Search

In the past decades, solar heat for industrial processes (SHIP) have been rapidly developed and applied, and also getting more attention in the world. China is still the largest energy consumer with industry accounting for almost 70% of total energy consumption. Low- and medium-temperature heat takes up 45% of process heat, holding 50%-70% of industrial energy consumption, which provides a favorable condition for solar application. China has built some demonstration projects to make industrial processes well integrated with solar heating systems. This paper briefly presents the status of China's energy consumption, integration of SHIP, as well as available solar technologies. 10 typical industrial sectors are selected to specifically describe their potential of SHIP. Moreover, 26 SHIP cases covering the 10 sectors in China are presented by field researches, with their capacity of energy saving and emissions reduction specifically investigated according to their own proportion of SHIP. The potential of SHIP in the selected 10 sectors are further predicted by optimistically and conservatively making their proportion of SHIP 5.5% and 2% respectively during the period of 2016-2020. The prediction shows that at least 39.40 million tons of coal equivalent and 98.22 million tons of CO2 emission can be reduced in 2020 in China's entire industrial sectors although solar supplies different proportions of heat demand in different industrial sectors.

Xiu-juan Gai,1,2 Yu-mei Wei,2 Heng-min Tao,1,2 Dian-zheng An,2 Jia-teng Sun,1,2 Bao-sheng Li2 1School of Medicine and Life Sciences, University of Jinan-Shandong Academy of Medical Sciences, Jinan, Shandong, People’s Republic of China; 2Department of Radiation Oncology VI, Shandong Cancer Hospital Affiliated to Shandong University, Jinan, Shandong, People’s Republic of China Purpose: This study was designed to compare the survival outcomes of temozolomide-based chemoradiotherapy (TMZ + RT) vs radiotherapy alone (RT-alone) for low-grade gliomas (LGGs) after surgical resection. Patients and methods: In this retrospective analysis, we reviewed postoperative records of 69 patients with LGGs treated with TMZ + RT (n=31) and RT-alone (n=38) at the Shandong Cancer Hospital Affiliated to Shandong University between June 2011 and December 2013. Patients in the TMZ + RT group were administered 50–100 mg oral TMZ every day until the radiotherapy regimen was completed. Results: The median follow-up since surgery was 33 months and showed no significant intergroup differences (P=0.06). There were statistically significant intergroup differences in the progression-free survival rate (P=0.037), with 83.9% for TMZ-RT group and 60.5% for RT-alone group. The overall 2-year overall survival (OS) rate was 89.86%. Age distribution (≥45 years and <45 years) and resection margin (complete resection or not) were significantly associated with OS (P=0.03 and P=0.004, respectively). Conclusion: Although no differences were found in the 2-year OS between the TMZ + RT and RT-alone groups, there was a trend toward increased 2-year progression-free survival in the TMZ + RT group. With better tolerability, concurrent TMZ chemoradiotherapy may be beneficial for postoperative patients with LGGs. Age distribution and surgical margin are likely potential indicators of disease prognosis. The possible differences in long-term survival between the two groups and